Navigation Links
New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer
Date:12/10/2008

ves of women with advanced breast cancer.

"Researching new cancer treatments is a complex step by step process. Each success helps lay the foundation for the next step forward," said William M. Burns, CEO Division Roche Pharmaceuticals. "These results show that we are making significant progress towards giving doctors and their breast cancer

patients better and more effective treatment options to fight this devastating disease at all stages," he added.

    Presentation of Data

    Herceptin

    Gianni L et al  Neoadjuvant trastuzumab in patients with   Friday 12th,
                    HER2-positive locally advanced breast      December
                    cancer: primary efficacy analysis of the   09:30 hrs
                    NOAH trial                                 General
                                                               Session 3
                                                               (Hall D)

    Xeloda

    Joensuu H et    Significant improvement in                 Sunday 14th,
    al. for The     recurrence-free survival (RFS)             December
    Finnish Breast  when capecitabine (X) is                   11:45 hrs
    Cancer Group    integrated into docetaxel (T)              General
                    5-FU + epirubicin + cyclophosphamide       Session 7
                    (CEF) adjuvant therapy for high-risk
                    early breast cancer (BC): interim
                    analysis of the FinXX-trial.

    Avastin

    Smith IE et al  Primary analysis of study MO19391, an      Saturday
                    open-label safety study of bevacizumab     13th,
                    plus taxane-based therapy as 1st-line      December
                    treatment of patients with locally         07:00 hrs
                    recurrent or metastatic breast cancer.     Poster
                                                               Session 4

'/>"/>
SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
5. Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers Symposium
6. Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer
7. Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
10. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
11. Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... , March 3, 2015  3-D printing could ... treatments to individual patient needs, with clinicians having ... size and shape. That,s according to a study ... Radiology ,s Annual Scientific Meeting . Researchers ... filaments that were bioactive, giving these devices the ...
(Date:3/3/2015)... March 3, 2015  KaVo Kerr Group, a global ... new products at the 36 th International Dental ... Kerr Group delivers products and solutions to 99% of ... trade fair for the dental industry — the ideal ... to offer. The meeting, March 10-14, 2015, expects more ...
(Date:3/3/2015)... 2015  CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... commercial focus on China , announces ... Executive Officer, will be making a corporate presentation at ... 8-11 in Dana Point, CA.  Dr. Ren will present ...
Breaking Medicine Technology:3-D printing offers innovative method to deliver medication 23-D printing offers innovative method to deliver medication 33-D printing offers innovative method to deliver medication 4KaVo Kerr Group Prepares to Present 35+ New Products at the 36th IDS in Cologne 2KaVo Kerr Group Prepares to Present 35+ New Products at the 36th IDS in Cologne 3CASI Pharmaceuticals To Present At The 27th Annual ROTH Conference 2
... OXIS International, Inc., (OTC Bulletin Board: OXIS ... Executive Officer, and Bernie Landes, President, will present to ... Sciences & Medical Technologies On-Line Forum on Thursday, February ... A webcast of the presentation will be ...
... Hardy Diagnostics, an ISO certified biomedical firm, is pleased ... selective chromogenic medium recommended for use as a primary ... Salmonella and Shigella spp. from stool ... non-pathogenic enteric bacteria based on colony color. Differentiation of ...
Cached Medicine Technology:The Only Chromogenic Medium That Detects Both Salmonella and Shigella! 2
(Date:3/3/2015)... 2015 Raritan Bay Medical Center is ... an interactive photo contest held at the Woodbridge Center ... To raise awareness for health and wellness in the ... their best health and wellness tips. , Photos of ... Center’s website and Facebook page where Facebook users voted ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Claflin ... the Department of Veterans Affairs has signed a new, ... March 1, 2015. , Under the contract, the ... such as the U.S. Military, Indian Health Services, National ... local government entities with competitive pricing for hospital equipment ...
(Date:3/3/2015)... A newly launched program is available ... II diabetes, and pre-diabetes. As opposed to traditional pharmaceutical ... for diabetes sufferers to reverse their disease without the ... In 2013, the U.S. diabetes industry made $250 billion ... include the use of insulin and other glucose-controlling medications ...
(Date:3/3/2015)... T-System Inc. today announced ... CPHQ, FABC as the company’s chief nursing officer along ... episodic care. , “Today’s patients are demanding ... including urgent care and freestanding emergency centers one of ... Davis, T-System’s chief executive officer. “We have a ...
(Date:3/3/2015)... March 03, 2015 The Data 360 ... at the Ford Conference Center, Dearborn, MI, on March 5, ... Inc., is a featured speaker. He is known internationally as ... , These designations were earned due to years of ... commercially-available NoSQL DB, released over 10 years ago. Subsequent developments ...
Breaking Medicine News(10 mins):Health News:Raritan Bay Medical Center Announces Winners of “Picture of Health” Photo Contest 2Health News:Claflin Medical Equipment (CME) Announces New 5 Year Contract with the Department of Veterans Affairs (VA) 2Health News:New Breakthrough In Diabetes Reaserch Show Scientifically Proven Way To Reverse Your Diabetes Naturally In 30 Short Days 2Health News:T-System Renews Commitment to Clinically-Driven Innovation and Appoints Industry Leader as CNO 2Health News:T-System Renews Commitment to Clinically-Driven Innovation and Appoints Industry Leader as CNO 3Health News:Scientel® to Present at Data 360 Big Data Healthcare Conference, March 5, 2015, Dearborn, MI 2Health News:Scientel® to Present at Data 360 Big Data Healthcare Conference, March 5, 2015, Dearborn, MI 3Health News:Scientel® to Present at Data 360 Big Data Healthcare Conference, March 5, 2015, Dearborn, MI 4
... looking into Tamiflu; Relenza also under scrutiny. , , ... Food and Drug Administration panel is meeting Tuesday ... flu drug Tamiflu (oseltamivir), linked recently to anecdotal ... , The FDA,s Pediatric Advisory Committee will begin ...
... STORZ OR1(R) GIVES SURGEONS, GREATER ACCESS TO PATIENT DATA AND ... ... REMOTELY, ALISO VIEJO, Calif., Nov. 27 Global Care Quest, ... Inc., the world leader in minimally invasive,endoscopic technologies and operating room integration, ...
... Nov. 27 Merge Healthcare (Nasdaq:,MRGE; TSX: ... services provider,announced today that its Merge Healthcare ... Gold Seal of Approval(TM), by demonstrating,compliance with ... national standard for healthcare quality and safety. ...
... million Series A financing from Alta Partners, ... ProQuest Investments and RiverVest Venture Partners, CARLSBAD, ... Pharmaceuticals, Inc. (Nasdaq: ISIS ) and Excaliard ... and develop antisense,drugs for the local treatment of ...
... green product design granted the International HIDO ... Award, TORONTO, and GOLFE JUAN, France, Nov. ... specializing in sustainable and health,product innovations and HIDO, ... has received the HIDO,International Design Award. The Award ...
... MAR, Calif., Nov. 27 ,Awake, the movie is a,psychological ... awareness" and finds himself awake and aware, but paralyzed,during heart ... ,Coma, captured and terrified,the American public,s imagination. ,Coma, is the ... surgery -- and never wake up again., "Five years ...
Cached Medicine News:Health News:FDA Mulls Tougher Warning Label on Kids' Flu Drugs 2Health News:FDA Mulls Tougher Warning Label on Kids' Flu Drugs 3Health News:KARL STORZ and Global Care Quest Announce Extension of Marketing Agreement 2Health News:KARL STORZ and Global Care Quest Announce Extension of Marketing Agreement 3Health News:Merge Healthcare Teleradiology Division Receives Accreditation From Joint Commission 2Health News:Merge Healthcare Teleradiology Division Receives Accreditation From Joint Commission 3Health News:Isis and Excaliard Collaborate to Develop Antisense Drugs for Local Treatment of Fibrotic Diseases 2Health News:Isis and Excaliard Collaborate to Develop Antisense Drugs for Local Treatment of Fibrotic Diseases 3Health News:Isis and Excaliard Collaborate to Develop Antisense Drugs for Local Treatment of Fibrotic Diseases 4Health News:Isis and Excaliard Collaborate to Develop Antisense Drugs for Local Treatment of Fibrotic Diseases 5Health News:Cooler Solutions' 'Dignity Toilet' Wins International Design Competition by Providing Sanitation for Those in Need 2Health News:'Awake' the Movie Highlights the Need for 'Goldilocks' Anesthesia, Says Dr. Barry L. Friedberg, Developer of Bispectral Index (BIS) Monitored Propofol Ketamine Sedation, Now Trademarked as Minimally Invasive Anesthesia (MIA)(R) 2Health News:'Awake' the Movie Highlights the Need for 'Goldilocks' Anesthesia, Says Dr. Barry L. Friedberg, Developer of Bispectral Index (BIS) Monitored Propofol Ketamine Sedation, Now Trademarked as Minimally Invasive Anesthesia (MIA)(R) 3
... Oxygen Conservation Device. Bypass ... ,6200 Accessories: , OCD870C ... CGA 540 Regulator , OCD2001-18 ... Booklet , CP2140 Vertical M-6 ...
... with Accutrol is similar in design to ... it incorporates a temperature probe at the ... probe can accurately determine the patient's core ... temperature accuracy comparable to a pulmonary artery ...
... These markers are available with 16 or 24 circular ... diameter, and an outer 9.5mm diameter. The markers are ... one single step for a 16 or 24 running ... points on the cornea to achieve a precise and ...
... Shafts For Insertion Through A 1.0mm Incision., ... ... A More Comfortable Approach., ,Recessed Jaws For ... For Protection Of Jaws During Sterilization., ,Reusable, ...
Medicine Products: